<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288729</url>
  </required_header>
  <id_info>
    <org_study_id>SU-01272011-7439</org_study_id>
    <nct_id>NCT01288729</nct_id>
  </id_info>
  <brief_title>Duration of Infusion Set Function: Quick-Set Teflon Catheter Versus Sure-T Steel Infusion Set Catheter</brief_title>
  <official_title>Duration of Infusion Set Function: A Study Comparing the Quick-Set Teflon Catheter vs Sure-T Steel Infusion Set Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label cross over study looking to compare the length of infusion set wear
      between a teflon catheter (Quick-Set) or a steel (Sure-T) catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently infusion sets are approved for 2-3 days of wear. In this study subjects will wear
      each infusion set for up to 7 days or until the infusion set fails. Subjects will alternate
      between wearing the Quick-Set Teflon catheter and the Sure-T steel catheter each week. They
      will wear each infusion set twice.

      For the study, subjects will be provided with an investigational Medtronic Real-Time
      Continuous Glucose Monitor (CGM) Enlite Sensor/Serter to help identify, serious hyperglycemia
      or hypoglycemia during the study. This sensor is not yet FDA approved, but is similar to
      commercially available sensors. If the sensor detects a high or low glucose, subject must
      obtain a fingerstick glucose to confirm the result. In the study, all insulin dose and other
      treatment decisions will be made using glucose meter results, and will not be based on sensor
      results. Subjects will be instructed on how to identify infusion set failures.

      Infusion set failure are defined as: 1) Blood ketones greater than 0.6 mmol/L, 2) Evidence of
      infection at the infusion site (such as redness of more than 4 mm), or 3) Blood glucose that
      does not decrease by at least 50 mg/dL within 1 hour of a correction bolus to treat a blood
      glucose greater than 300 mg/dL.

      Subjects will follow-up weekly in one of our test centers for a total of five visits.

      At home subjects will be asked to keep a log recording measurements of redness and induration
      at the infusion site when it is changed prior to the study visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Wear of Infusion Site</measure>
    <time_frame>5 weeks</time_frame>
    <description>Comparison of the length of wear (hours) of Sure-T Steel Infusion Set Catheter versus Quick-Set Teflon Catheter. Infusion sets are currently approved for wear 2-3 days (24-72 hours). Participants wore each set for up to 7 days twice. Outcome measure is presented according to the intervention (Steel or Teflon catheter).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1 - Steel Cathetar, then Teflon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Teflon Cathetar, the Steel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sure-T Steel Infusion Set Catheter</intervention_name>
    <description>Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time</description>
    <arm_group_label>Group 1 - Steel Cathetar, then Teflon</arm_group_label>
    <arm_group_label>Group 2 - Teflon Cathetar, the Steel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quick-Set Teflon Catheter</intervention_name>
    <description>Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time</description>
    <arm_group_label>Group 1 - Steel Cathetar, then Teflon</arm_group_label>
    <arm_group_label>Group 2 - Teflon Cathetar, the Steel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump
             for at least 3 months

          -  The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide
             level and antibody determinations are not needed.

          -  Age 12 to 45 years

          -  For females, not currently known to be pregnant

          -  An understanding of and willingness to follow the protocol and sign the informed
             consent

          -  Hemoglobin A1c level less than or equal to 10%

          -  Medtronic Continuous subcutaneous insulin infusion pump

          -  Must be able to understand spoken or written English

        Exclusion Criteria:

          -  Diabetic ketoacidosis in the past 6 months

          -  Severe hypoglycemia resulting in seizure or loss of consciousness in the 6 months
             prior to enrollment

          -  Current treatment for a seizure disorder

          -  Cystic fibrosis

          -  Active infection

          -  A known medical condition that in the judgment of the investigator might interfere
             with the completion of the protocol such as the following examples:

          -  Inpatient psychiatric treatment in the past 6 months for either the subject or the
             subject's primary care giver (i.e., parent or guardian)

          -  Presence of a known adrenal disorder

          -  If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of
             stability on the medication for the past 2 months prior to enrollment in the study

          -  Abuse of alcohol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce A. Buckingham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Patel PJ, Benasi K, Ferrari G, Evans MG, Shanmugham S, Wilson DM, Buckingham BA. Randomized trial of infusion set function: steel versus teflon. Diabetes Technol Ther. 2014 Jan;16(1):15-9. doi: 10.1089/dia.2013.0119. Epub 2013 Oct 3.</citation>
    <PMID>24090124</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <results_first_submitted>October 28, 2015</results_first_submitted>
  <results_first_submitted_qc>January 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2017</results_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Bruce A. Buckingham</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Steel Cathetar, Then Teflon</title>
          <description>Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - Teflon Cathetar, the Steel</title>
          <description>Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - Steel Cathetar, Then Teflon</title>
          <description>Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - Teflon Cathetar, the Steel</title>
          <description>Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.3" spread="8.8"/>
                    <measurement group_id="B2" value="22.3" spread="8.8"/>
                    <measurement group_id="B3" value="22.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Wear of Infusion Site</title>
        <description>Comparison of the length of wear (hours) of Sure-T Steel Infusion Set Catheter versus Quick-Set Teflon Catheter. Infusion sets are currently approved for wear 2-3 days (24-72 hours). Participants wore each set for up to 7 days twice. Outcome measure is presented according to the intervention (Steel or Teflon catheter).</description>
        <time_frame>5 weeks</time_frame>
        <population>Participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sure-T Steel Infusion Set Catheter</title>
            <description>Participants will wear Sure-T Steel Infusion Set Catheter for 7 days (for a total of 14 days for the duration of the study)
Sure-T Stell Infusion Set Catheter: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
Quick-Set Teflon Catheter: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time</description>
          </group>
          <group group_id="O2">
            <title>Quick-Set Teflon Catheter</title>
            <description>Participants will wear the Quick-Set Teflon catheter for 7 days (for a total of 14 days for the duration of the study).
Sure-T Stell Infusion Set Catheter: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
Quick-Set Teflon Catheter: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Wear of Infusion Site</title>
          <description>Comparison of the length of wear (hours) of Sure-T Steel Infusion Set Catheter versus Quick-Set Teflon Catheter. Infusion sets are currently approved for wear 2-3 days (24-72 hours). Participants wore each set for up to 7 days twice. Outcome measure is presented according to the intervention (Steel or Teflon catheter).</description>
          <population>Participants with available data were analyzed.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" lower_limit="87" upper_limit="168"/>
                    <measurement group_id="O2" value="145" lower_limit="99" upper_limit="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 weeks</time_frame>
      <desc>Safety data is presented according to the intervention (Steel or Teflon catheter).</desc>
      <group_list>
        <group group_id="E1">
          <title>Sure-T Steel Infusion Set Catheter</title>
          <description>Participants will wear Sure-T Steel Infusion Set Catheter for 7 days (for a total of 14 days for the duration of the study)
Sure-T Stell Infusion Set Catheter: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
Quick-Set Teflon Catheter: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time</description>
        </group>
        <group group_id="E2">
          <title>Quick-Set Teflon Catheter</title>
          <description>Participants will wear the Quick-Set Teflon catheter for 7 days (for a total of 14 days for the duration of the study).
Sure-T Stell Infusion Set Catheter: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
Quick-Set Teflon Catheter: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ketosis</sub_title>
                <description>serum ketones &gt;0.6 mmol/L</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin reaction to infusion set</sub_title>
                <description>redness and/or induration</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a single center study with 20 subjects enrolled in a cross-over study. A larger study would make results more robust. In addition, if each subject had worn each infusion set 3 to 6 times, it would make the study more robust.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bruce Buckingham</name_or_title>
      <organization>Stanford Childrens Health</organization>
      <phone>650725-6549</phone>
      <email>buckingham@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

